respectively; p<0.001). A difference in the IVCCM parameter corneal nerve fibre length (CNFL) was observed across all groups (p¼0.004), lowest among clinical cases. For the identification of clinical cases, CNFL had an AUC of 0.64 and optimal threshold of <14.6 mm/mm 2 (66% sensitivity, 59% specificity). For preclinical cases, AUC was 0.74 with an optimal threshold value of <16.8 mm/ mm 2 (78% sensitivity, 69% specificity). In the validation set, the AUC for identifying both clinical and preclinical cases was 0.55. Conclusions: Small nerve fibres appear to be impaired at very early stages of T2D. However, in contrast to research in T1D where performance is excellent, diagnostic performance of IVCCM for neuropathy screening in T2D may be limited by the higher neuropathy prevalence. 35 Characteristics of Canadians with 50 Years of Type 1 Diabetes: Preliminary Description of the Canadian Study of Longevity in Diabetes ELISE HALPERN, LEIF LOVBLOM, ALANNA WEISMAN, HILLARY KEENAN, MICHAEL BRENT, DAVID CHERNEY y , NARINDER PAUL, VERA BRIL y , BRUCE PERKINS * y Toronto, ON; Boston, MA Background: Longevity studies have shown that type 1 diabetes (T1D) subjects can survive for extreme duration of the disease without retinopathy and nephropathy, but estimates of neuropathy are uncertain. General studies suggest that lifetime neuropathy risk may approach 100%. In a national cohort with 50 years or more of T1D, we aimed to assess the prevalence of microvascular compli- cations and other indicator variables. Methods: We surveyed participants by advertisement and mail- ings to healthcare professionals across Canada. We assessed self- reported complications and also quantitatively using retinopathy defined by eye specialist fundus examinations, neuropathy defined by a Michigan Neuropathy Screening Instrument score >2, and nephropathy defined by an eGFR<60mL/min/1.73 m 2 or urine al- bumin-to-creatinine ratio >2 mg/mmoL. Results: The 127 (of 300 projected) participants (57% female) had median diabetes duration of 55 [52,59] and a mean age of 66.48.6 years, BMI of 25.74.5 kg/m 2 , and recent HbA1c of 7.51.0%. Fifty- five (43%) reported insulin pump use, 104 (82%) attended 2 physician visits per year and 91 (72%) reported seeing an endocri- nologist for their care. Eighty-four (66%) reported use of renin- angiotensin-system inhibitors. Qualitatively, retinopathy was most prevalent at 60% when compared to neuropathy (35%) and ne- phropathy (11%, p<0.001 for all comparisons). Quantitatively, retinopathy was most prevalent at 72% as compared to nephropa- thy (56%) and neuropathy (30%, p<0.001 for all comparisons). Conclusions: Respondents with longstanding T1D had salutary factors, such as high rates of insulin pump use, specialist care and good glycemic control, but frequent retinopathy and nephropathy. Against hypothesis, neuropathy appeared to occur at the lowest frequency. 36 Abnormal Mitochondrial Bioenergetics in Platelets of Healthy Subjects with a Family History of Diabetes MANOJ MOHANAN NAIR * , SUBIR ROY CHOWDHURY, PAUL FERNYHOUGH, GARRY SHEN Winnipeg, MB Platelets may serve as an amenable tissue for detection of mito- chondrial dysfunction, a plausible early biomarker of disease. Previ- ous studies have demonstrated that platelets from type 2 diabetes patients had lower mitochondrial membrane potential, membrane fluidity, higher adenosine triphosphate content and mitochondrial oxidative stress. However, the impact of family history of diabetes on platelet mitochondrial bioenergetics remains unknown. We investigated the impact of family history of diabetes or heart disease or dyslipidemia on mitochondrial bioenergetics in the intact human platelets from 49 (14 males and 35 females) healthy fasting donors (38.3313.50 years) by determining the oxygen consumption rates in intact platelets using a highly sensitive Clark- type oxygen electrode and analyzed by Datlab (Oroboros, Austria). Mitochondrial bioenergetic profiles in the healthy subjects were not significantly affected by age, gender or body mass index. However, healthy subjects with a family history of diabetes alone had significantly lower basal, maximal and ATP-linked respiration (p<0.05 or 0.01), significantly high non-mitochondrial respiration levels when compared to healthy subjects without a family history of diabetes, heart disease or dyslipidemia (p<0.05 or 0.01). These results suggest that mitochondrial bioenergetics can be conveniently assessed using platelets from peripheral blood. Healthy subjects with a family history of diabetes alone exhibited detectable abnormalities in their platelet mitochondrial bio- energetics. The assessment of mitochondrial bioenergetics may help to identify clinically healthy subjects with early signs of mitochondrial dysfunction. 37 SHP-1 Activation by Hyperglycemia Inhibits PDGF’s Pro- Angiogenic Effects in Hypoxic Smooth Muscle Cells MARTIN PARÉ * , MARIE-ODILE GUIMOND, PEDRO GERALDES Sherbrooke, QC Multiple studies suggested that hyperglycemia is responsible for growth factor deficiency such as the platelet-derived growth factor (PDGF) causing poor collateral vessel formation and lower limb amputation in diabetic patients. Our laboratory has recently pub- lished that increased SHP-1 expression in diabetic mice (DM) is associated with decreased PDGF actions, an important factor mediating vascular smooth muscle cells (vSMC) migration and proliferation. Therefore, to investigate the mechanism by which SHP-1 is involved in PDGF signalling pathway inhibition, vSMC were exposed to normal (NG; 5.6 mmol/L) or high glucose levels (HG; 25 mmol/L) for 48 h either in normoxia (20% O2) or hypoxia (w1% O2) during the last 24 hours prior PDGF stimulation. We observed that cell proliferation induced by PDGF (10 ng/mL) in NG was significantly blunted when vSMC were exposed to HG in both normoxia and hypoxia (p¼0.0046 and p¼0.0301, respectively). Moreover, both HG and hypoxia conditions were necessary to inhibit vSMC migration induced by PDGF. The signalling pathway of PDGF was evaluated and 30% decrease in Akt phosphorylation was observed in vSMC exposed to HG treatment in normoxia and hypoxia. In contrast, no significant effect was noted on ERK phos- phorylation. Although SHP-1 expression was not affected, its phosphatase activity was increased in HG under normoxia and hypoxia. Furthermore, SHP-1 association with PDGF receptor was elevated in HG and hypoxia conditions. In conclusion, hyperglyce- mia, either alone or in combination with hypoxia, activates SHP-1 leading to PDGF signalling pathway inactivation in vSMC contrib- uting to loss of the angiogenic properties of PDGF in diabetes. 38 Association of Structured Physical Activity with Blood Glucose Control in Patients with Type 1 Diabetes: A Systematic Review and Meta-Analysis JANE YARDLEY * , JACQUELINE HAY, AHMED ABOU-SETTA, SETH MARKS, JONATHAN MCGAVOCK Camrose, AB; Winnipeg, MB Physical activity is recommended for individuals with type 1 diabetes (T1D); however, its impact on blood glucose control (i.e. HbA1c) remains unclear. Studies to date have been sparse, Abstracts / Can J Diabetes 38 (2014) S2eS24 S15